ReviewCurrent treatment options in allergy2017
Update on Biomarkers to Monitor Clinical Efficacy Response During and Post Treatment in Allergen Immunotherapy.
Review in Current treatment options in allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Sublingual immunotherapy for 4 years increased the number of Foxp3Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Trial
- Review
- Comparative clinical efficacy and immunological modulation of subcutaneous vs. sublingual allergen immunotherapy in children with house dust mite-induced allergic asthma: a retrospective cohort study.Frontiers in medicine · 2026Article
- The immune tolerance role of Bregs in inhibiting human inflammatory diseases, with a focus on diabetes mellitus.Frontiers in immunology · 2025Review
- Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.International journal of molecular sciences · 2024Review
- Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy.Biomedicines · 2022Article
- Mast Cell Desensitization in Allergen Immunotherapy.Frontiers in allergy · 2022Review
- B Cell Functions in the Development of Type I Allergy and Induction of Immune Tolerance.Handbook of experimental pharmacology · 2022Article
- Dogmas, challenges, and promises in phase III allergen immunotherapy studies.The World Allergy Organization journal · 2021Review
- Allergen Immunotherapy: Biomarkers and Clinical Outcome Measures.Journal of asthma and allergy · 2021Review
- Mapping Human Monoclonal IgE Epitopes on the Major Dust Mite Allergen Der p 2.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Fasciola gigantica excretory-secretory products (FgESPs) modulate the differentiation and immune functions of buffalo dendritic cells through a mechanism involving DNMT1 and TET1.Parasites & vectors · 2020Article
- Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies.Bioscience reports · 2020Review
- Biomarkers in Food Allergy Immunotherapy.Current allergy and asthma reports · 2019Review
- Comparison of Long-term Efficacy of Subcutaneous Immunotherapy in Pediatric and Adult Patients With Allergic Rhinitis.Allergy, asthma & immunology research · 2019Article
- The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses.Clinical reviews in allergy & immunology · 2018Review
- The role of basophils as innate immune regulatory cells in allergy and immunotherapy.Human vaccines & immunotherapeutics · 2018Review
- IL-10, TGF-β, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells.The Journal of allergy and clinical immunology · 2018Article
- Immunological Mechanisms in Allergic Diseases and Allergen Tolerance: The Role of Treg Cells.Journal of immunology research · 2018Review
- Contributions and Future Directions for Structural Biology in the Study of Allergens.International archives of allergy and immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Allergen immunotherapy (AIT) is an immune modulating treatment for allergic diseases. Although highly effective, some patients do not respond to the treatment. To date there are no surrogate biomarkers that are predictive of the clinical response to AIT. More and more is known about the underlying immunological mechanism involved in AIT. Through modulation of both innate and adaptive immune responses, involving reduced ILC2 and enhanced Treg and Breg induction and functionality, along with induction of IgG4 antibody production which have the capacity to inhibit both allergen-induced basophil responsiveness and CD23-mediated IgE-facilitated allergen presentation, the result is an immune skewing towards a more balanced Type I response. So far, however there is not a clear correlation with the observed immunological changes and predictive correlates of clinical efficacy. The most promising biomarker of successful AIT is IgE-FAB as a reflection of functional IgG4. Cellular responses and cytokine analysis gives a great deal of insight into the mechanisms of AIT but may not represent useful or indeed reliable biomarkers in a clinical setting. There is a need for more research for confirmation and interpretation of the possible association with biomarkers and clinical response to AIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.